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Melanoma, like most cancers, is a disease that wreaks havoc mostly through its propensity
to spread and establish secondary tumors at sites that are anatomically distant from the
primary tumor. The consideration of models of cancer progression is therefore important
to understand the essence of this disease. Previous work has suggested that melanoma
may propagate according to a cancer stem cell (CSC) model in which rare tumorigenic
and bulk non-tumorigenic cells are organized into stable hierarchies within tumors. How-
ever, recent studies using assays that are more permissive for revealing tumorigenic poten-
tial indicate that it will not be possible to cure patients by focusing research and therapy on
rare populations of cells within melanoma tumors. Studies of the nature of tumorigenic
melanoma cells reveal that these cells may gain a growth, metastasis and/or therapy resis-
tance advantage by acquiring new genetic mutations and by reversible epigenetic mecha-
nisms. In this light, efforts to link the phenotypes, genotypes and epigenotypes of
melanoma cells with differences in their in vivo malignant potential provide the greatest
hope of advancing the exciting progress finally being made against this disease.
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of this disease.
Conceptually, cancer propagation is proposed to occur
according to various models, each of which provides an inde-
pendent explanation of the phenotypic and functional hetero-
geneity that is often apparent among cells within a malignant
tumor. The first is the cancer stem cell (CSC) model (Dick,
2008; Lobo et al., 2007; Reya et al., 2001), in which tumor
growth is primarily driven by rare populations of highly tu-
morigenic cells that not only renew their own malignant po-
tential, but also give rise to bulk populations of other cells
that are irreversibly less- and/or non-tumorigenic. Second is
the clonal evolution model (Fearon and Vogelstein, 1990;
Foulds, 1958; Lengauer et al., 1998; Nowell, 1976), in which
a high proportion of cells in a cancer has the potential to drive
disease progression and in which certain cells acquire addi-
tional genetic mutations that provide an advantage in growth
and/or metastasis capability. More recently, the separate no-
tion of cancer cell plasticity, or interconversion, has been in-
creasingly recognized in the literature as contributing to
cancer cell heterogeneity and progression of malignant dis-
ease (Gupta et al., 2009; Mani et al., 2008; Marusyk and
Polyak, 2010; Pinner et al., 2009; Roesch et al., 2010; Sharma
et al., 2010). The interconversion model refers to reversible
switching of cancer cells between more and less actively ma-
lignant behaviors thatmay be associated with phenotypic dis-
tinctions and differences in therapy responsiveness between
cells. In fact, although these models are conceptually quite
different, they are not mutually exclusive, and it is likely
that at least some cancers use more than one of these models
at different stages, or even simultaneously, during their evolu-
tion in a patient (Marusyk and Polyak, 2010; Shackleton, 2010).
How doesmelanoma progress? From a clinical perspective,
melanoma is generally considered to be a highly aggressive
cancer, although a small subset of patients with metastatic
melanoma has a relatively indolent disease course (Tsao
et al., 2004). Histologically, mitoses are frequently apparent
in sections of melanoma tumors and staining for proliferative
markers such as Ki67 is usually positive (Ohsie et al., 2008). In
this light, it would be surprising if melanoma progressed
according to a model in which tumorigenic cells were rare.
However, cellular heterogeneity is also a histological feature
of many melanomas, and studies of cell surface marker ex-
pression indicate that multiple, phenotypically distinct sub-
populations of melanoma cells exist within tumors (Fang
et al., 2005; Quintana et al., 2008; Schatton et al., 2008).
The basis of this heterogeneity has been the subject of in-
tense debate among melanoma biologists e and rightfully
so. If melanoma cell heterogeneity develops in the context
of a CSCmodel, then separate identification, study and thera-
peutic targeting of the rare tumorigenic cell population should
result in great clinical benefit to patients. Furthermore, study-
ing melanoma tumors as a whole is likely to mask the critical
drivers of melanoma progression if these drivers are only
present in a rare minority of the cells. However, if a high pro-
portion of melanoma cells has tumorigenic potential and is
subject to ongoing and extensive genetic and/or epigenetic
change, the implications for managing this disease would be
profound. For example, targeting single oncogenic mecha-
nisms to which tumors are supposedly ‘addicted’ (Weinsteinand Joe, 2008) may be only fleetingly beneficial in genetically
unstable melanomas in which resistance mechanisms rap-
idly emerge. Similarly, cancer cells that are able to avoid
therapeutic intervention by transiently switching to epigenet-
ically-determined states of resistance may require a multi-
pronged treatment approach (Sharma et al., 2010).2. Melanoma and the cancer stem cell model
Several studies have correlated the phenotypic heterogeneity
of melanoma cells with differences in cell behaviour. Fang
et al. (2005) evaluated in vitro clonogenicity in melanoma cells
by utilizing their ability to form spherical aggregates of cells in
non-adherent culture conditions. Spherogenicity was identi-
fied in only a proportion of cells isolated from melanoma tu-
mors, and at least some cells derived from spheres could
form tumors when transplanted into immunocompromised
mice. Heterogeneity of CD20 expression was noted among
cells derived from melanoma sphere cultures, and cells from
the CD20þ subpopulation showed a greater capacity to form
secondary spheres than CD20 cells, suggesting an associa-
tion betweenmarker expression and clonogenicity in cultured
melanoma cells. In support of this concept, Gedye et al. (2009)
identified subpopulations of CD133þ cells in early passage
melanoma cell lines that displayed increased clonogenicity
in soft agar culture comparedwith CD133 cells. Interestingly,
in this study no differences in two-dimensional adherent
growth were seen between cells according to expression of
CD133, indicating that culture conditions can affect the evalu-
ation of clonogenicity in melanoma cells.
An important question arising from these studies is
whether the cells that were not clonogenic in vitro were tu-
morigenic in vivo. Tumorigenicity, a key component of malig-
nant behaviour, is a property of cancer cells that by definition
can only be demonstrated in vivo. Although clonogenic poten-
tial must exist in a cell for tumor formation to occur, it is not
knownhowwell thenormal in vivo environment that supports
clonogenic tumor growth in patients is recapitulated in vitro.
In fact, melanoma cells isolated from patients are often diffi-
cult to grow in culture, despitedisplayingovert tumorigenicity.
We have tested melanoma cells purified from six tumors
obtained frompatientswithmetastatic disease for their ability
to formcolonies in culture conditions thatwe have found to be
supportive of melanoma cell growth (Fig. 1a). Each melanoma
contained a high proportion (13%e70%) of cells with tumori-
genic potential when evaluated in immunocompromised
NOD/SCID IL2Rg/ (NSG) mice, a highly permissive model
for this purpose (Quintana et al., 2008). However, only four of
thesemelanomas contained cells that proliferated and formed
colonies in non-adherent culture. In three experiments, we
also cultured cells adherently after plating on tissue culture-
treated plastic (adherent culture on Matrigel did not increase
the detectable frequency of clonogenic cells compared to cul-
ture on plastic; data not shown). Although the frequency of de-
tectable clonogenic cells was generally higher in adherent
culture than in non-adherent culture (Fig. 1a), in most cases
the proportion of colony-forming cells identified in any culture
condition was several-fold lower than the proportion of
tumor-forming cells identified in NSG mice (Fig. 1a). Notably,
Figure 1 e In vitro culture of human melanoma cells. (A) Comparison of the in vivo tumorigenicity and the in vitro clonogenicity of melanoma
cells. The frequency of tumorigenic cells was evaluated in melanomas obtained from six patients by limiting dilution or single cell transplantation
assays into NSG mice (Quintana et al., 2008). Cells from the same tumors were also grown in vitro non-adherently (using ultra-low binding 6-well
plates (Corning)) and in some cases adherently (using tissue culture-treated 6-well plates (Corning)) at clonal density using otherwise identical
culture conditions (6.5% CO2) and media (50% DMEM-low, 30% Neurobasal (Invitrogen), 15% CEE (Stemple and Anderson, 1992), 1% Pen/
Strep, 1% non-essential amino acids (Gibco), 117 nM retinoic acid, 50 mM 2-mercaptoethanol, (Sigma), 1% N2 supplement, 2% B27 supplement
(Gibco), 20 ng/mL recombinant human bFGF, 20 ng/mL IGF-1 (R&D systems)). In vitro clonogenicity is shown as the mean (±s.d.) percentage of
plated cells that formed colonies in either culture condition (percentages derived from up to four independent experiments per melanoma, each one
including cells plated into three separate wells). In some experiments, cells were cultured side-by-side either on tissue culture-treated plastic or
after embedding cells in 25% Matrigel. No significant differences were observed in the frequency of clonogenic cells identified in either of these
adherent culture conditions (data not shown). The frequency of clonogenic cells identified in vitro was in every case lower than the empirically
determined tumorigenic cell frequency in NSG mice. In two melanomas (205 and 308) that displayed robust tumorigenicity in NSG mice,
melanomaspheres could not be generated at all and adherent colony formation was poor. Overall, in vitro clonogenicity was a poor surrogate for in
vivo tumorigenicity in these experiments. (BeC) Representative pictures of adherent (B) and non-adherent spherogenic (C) colony formation in
primary human melanoma cell cultures (cells derived from patient 214, see A). (D) Cells obtained from two different patients and cultured either
adherently or non-adherently (A) for 3 weeks were transplanted subcutaneously into NOD/SCID mice. Limiting dilution analysis (Hu and Smyth,
2009) was used to calculate the frequency of tumorigenic cells derived in each culture condition, based on the proportion of tumors that developed
in mice per transplanted cell number. Tumorigenic cell frequencies were similar in human melanoma cells cultured adherently and non-adherently.
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quency of cells in each culture condition that were tumori-
genic in vivo, no significant differences were apparent
between cells cultured adherently or non-adherently
(Fig. 1bed). Although these latter experimentswere performed
using suboptimal tumorigenesis assays (NOD/SCIDmicewith-
out Matrigel) and the observations need to be confirmed in
more permissive assays (NSG mice with Matrigel), the data
suggest that in comparisonwith adherent culture, non-adher-
ent culture does not enhance themaintenance of tumorigenic
melanoma cells. We thus find that in vitro clonogenicity is an
inadequate surrogate for melanoma cell tumorigenicity, at
least in commonly used culture conditions. The development
of in vitro assays that reliably predict in vivomalignant poten-
tial ofmelanoma cells is a high priority inmelanoma research.
Other studies have tested directly the tumorigenicity of
phenotypically distinct human melanoma cells using in vivo
tumorigenesis assays. The approach in these studies is ap-
pealing because cells were isolated and transplanted directly
from tumors, without an intervening in vitro culture step.Because of this, artificial changes in malignant potential that
may be induced in cancer cells through extended ex vivo ma-
nipulation are minimized. Indeed, the tremendous progress
and enthusiasm in the CSC field over the last 10e15 years
can be largely attributed to the development of immunocom-
promised mouse models that permit the growth of human
cancer cells obtained directly from patient tumors. Monzani
et al. (2007) found that CD133 expression was associated
with increased tumorigenicity in cells isolated directly from
seven metastatic patient tumors and evaluated by transplan-
tation into immunocompromised NOD/SCID mice. In this
study, injection of CD133þ cells produced tumors in the mice
after only 40e50 days, whereas no tumors arose from
CD133 cells after 4 months. Similarly, Schatton et al. (2008)
identified a subpopulation of human melanoma cells that
was characterized by expression of the multidrug transporter
molecule ABCB5 and by enriched tumorigenicity in NOD/SCID
mice. In this study, the empirically determined overall fre-
quency of tumorigenic cells in themelanomas studiedwas ap-
proximately 1 in a million, and the tumorigenic cell frequency
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portantly, targeting of ABCB5þ cells with monoclonal anti-
bodies inhibited tumor growth in xenograft melanoma
models, highlighting the potential of identifying and targeting
rare tumorigenic cells in cancer therapy. Collectively, these
studies suggested that melanoma could propagate according
to a CSC model in which tumorigenic cells were rare and
gave rise to phenotypically distinct non-tumorigenic cells in
a stable and hierarchical manner.3. Evidence that melanoma does not follow a cancer
stem cell model
However, other studies of melanoma cell tumorigenicity sug-
gest that this may not be the case. In light of reports that
raised questions about the effects of xenotransplantation on
the detection of human cell tumorigenicity by showing that
tumorigenic cells were not rare in syngeneic transplantation
studies of mouse cancers (Kelly et al., 2007; Williams et al.,
2007), we decided to re-evaluate the humanmelanoma tumor-
igenesis assay. These experiments revealed three parameters
that affected the ability of human melanoma cells to form tu-
mors in immunodeficient mice: 1) assay duration, 2) the de-
gree of immunodeficiency in recipient mice, and 3) the
immediate extracellular environment into which melanoma
cells are transplanted. Whenwe altered the tumorigenesis as-
say to include a longer post-transplant monitoring time, the
use of NSG mice as recipients, and pre-embedding cells in
Matrigel prior to transplantation, we observed a roughly
5000-fold increase in the ability to detect tumorigenic mela-
noma cells compared with published assay conditions
(Quintana et al., 2008). In a series of extended experiments
evaluating in these modified assay conditions cells obtained
directly from six patients with metastatic melanoma, the av-
erage frequency of tumorigenic cells was 25% (Quintana
et al., 2008). The simplest interpretation of these experiments
is that metastatic melanoma contains a high proportion of
cells with intrinsic tumorigenic potential that are not appar-
ent when tumorigenicity is evaluated in assays less permis-
sive for allowing tumor formation.
Since then, others have also found clonogenicity and/or tu-
morigenicity to be present in a high proportion of melanoma
cells. Prasmickaite etal. (2010)demonstrated that ahighpropor-
tion of melanoma cells in established cultures could be clono-
genic. Zhong et al. (2010) found that >10% of cells in the B16-
F10mousemelanoma cell line were tumorigenic in the context
of syngeneic transplantation. Held et al. (2010) found tumorige-
nicity to be a common property of melanoma cells in different
mouse models. Notably in this study, single cells isolated from
the large CD34þ fraction of tumors carrying an activated BRAF
mutation and lacking the tumor suppressor PTEN formed a tu-
mor in every case (six secondary tumors arose from six CD34þ
single cell injections in two independent experiments). This in-
dicates that a large proportion of melanoma cells in this model
havetumorigenicpotential. Interestingly, evidenceofhierarchi-
cal organization was not present in the highly tumorigenic
CD34þ fraction, but was observed in less-tumorigenic CD34
cells, which were distinguished by p75 expression; CD34p75
cells produced tumors containing both p75 andp75þ fractions,whereas CD34p75þ cellswere not tumorigenic in single cell tu-
morigenesis assays. This raises the possibility that ongoingmu-
tations in transformed cells may produce biologically distinct
tumorigenic clones within the same tumor: those that produce
non-tumorigeniccellsandthose thatdonot.Overall, thesestud-
ies andourownresults support theconclusion that tumorigenic
potential is frequently present in melanoma cells and indicate
that this disease does not progress according to a CSC model
characterized by rare tumorigenic cells.4. The NSG tumorigenesis assay
Could the NSG tumorigenesis assay overestimate tumorigenic
potential in melanoma cells? We believe not, as by definition
potential can never be overestimated, only concealed. It is
highly unlikely that non-tumorigenic melanoma cells were
rendered tumorigenic by exposure to Matrigel or the subcuta-
neous tissues of NSG mice, as the same assay conditions did
not transform normal human melanocytes (Quintana et al.,
2008). Therefore, the transplanted cells that formed tumors
must have harbored an intrinsic potential to do so. During
neoplastic transformation a cell acquires malignant potential,
including the capacity for tumor formation. In a patient, this
potential may not be apparent in every cell at every moment.
For example, some cells may be actively proliferating and
others dormant, in part regulated by environmental influ-
ences. However, the non-proliferating cells can be said to har-
bor tumorigenic potential if in a different circumstance they
proliferate actively and contribute to tumor formation. In
a conceptually similar way, a cancer cell may still have tumor-
igenic potential, even if a particular assay does not reveal it.
This can be shown if other assay conditions allow that same
cell to form tumors. We contend that the NSG tumorigenesis
assay does not make melanoma cells tumorigenic. Rather, it
reveals tumorigenic potential that is already present in cells
but can be hidden in other assays.
Of course, not every cell with tumorigenic potential will
contribute tomelanomaprogression in a patient. Tumorigenic
potential in some melanoma cells may be transiently or per-
manently suppressed in patients by cell-extrinsic mecha-
nisms, such as anti-tumor immune effects or metabolic
insufficiency. Some cells may even be killed by these mecha-
nisms. Additionally, tumorigenic potential could be irrevers-
ibly lost in some cells through cell-intrinsic mechanisms,
such as stable epigenetic changes (as proposed in the CSC
model) or the acquisition of deleterious genetic changes (that
could occur in the context of clonal evolution). In a patient, it
is not possible to test which cells with tumorigenic potential
will andwill not propagate disease, as in vivo studies of synge-
neic human melanoma cell transplantation are not ethical.
Therefore, a cell that is demonstrated to be intrinsically tumor-
igenic in any assay system should be considered to be poten-
tially tumorigenic in a patient. It is not safe to ignore in
therapy cancer cells that are non-tumorigenic only under cer-
tain assay conditions.
A further question arising from our studies of melanoma
cell tumorigenicity in NOD/SCID andNSGmice regards the po-
tential role of natural killer (NK) cell function in modifying the
course of melanoma progression in patients. NSG mice differ
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(Shultz et al., 2005). In side-by-side assays comparing directly
melanoma cell tumorigenicity in NOD/SCID vs NSG mice, we
found up to over 100-fold increase in the frequency of tumor-
igenic cells in the NSG model (Quintana et al., 2008). This sug-
gests a critical role for NK cells in inhibiting the tumorigenicity
of human melanoma cells in NOD/SCID mice. However, care
must be taken in extrapolating these results to the ways in
which NK cells in patients may limit human melanoma pro-
gression. The xenogeneic immune response in NOD/SCID
mice against humanmelanoma cells is likely to be fundamen-
tally different to the immune response mounted by patients
against their own melanoma. NK cells may be important in
the xenogeneic rejection of transplanted cells (Yang and
Sykes, 2007), but strong evidence of dominant NK cell-medi-
ated anti-tumor effects in patients, equivalent to the elimina-
tion of the vast majority of transplanted human melanoma
cells we observed in NOD/SCID mice, is lacking (Wallace and
Smyth, 2005). Efforts to understand and enhance NK cell kill-
ing of cancer cells in patients are clearly worthwhile, but our
experience comparing human melanoma cell tumorigenesis
in NSG and NOD/SCIDmice does not necessarily justify them.5. The nature of tumorigenic melanoma cells
Ifmelanomadoesnot followacancerstemcellmodelcharacter-
ized by rare tumorigenic cells, a fundamental question then
arises as to how the disease grows and spreads with such fre-
quently lethal rapidity in patients. Specifically, to what degree
do interconversionand clonal evolutionplay a role indetermin-
ing thenatureof the largeandhighlymalignant tumorigeniccell
component of these cancers? Currently, the answers to these
questions are unknown. However, evidence exists that both
models of cancer progressionmaybe relevant tounderstanding
the mechanisms that drive melanoma propagation.
For interconversion, there is evidence that melanoma cells
can display plasticity. For example, phenotypic (Bennett, 1983)
and functional (Hoek et al., 2008) switching of melanoma cells
betweendifferent states of cell pigmentation andproliferation,
respectively, has been described. Expression of Brn-2, amedia-
tor of melanocyte differentiation through its repressive effects
on MITF, was observed by intra-vital imaging to be heteroge-
neouslyand transientlypresent in transplantedtumorsderived
fromtheB16mousemelanomacell line, andassociatedwith re-
duced pigmentation and increased cell invasiveness (Pinner
et al., 2009). JARID1B, which modulates chromatin structure
viademethylaseactivityathistone3K4,wasfoundtobehetero-
geneously and reversibly expressed in melanoma cell lines in
a way that correlated with an enhanced ability to support
long-term tumorigenesis (Roesch et al., 2010). Our own studies
of expression of the cell surface marker CD133 have identified
heterogeneous expression in some melanomas. In contrast to
other cancers (O’Brien et al., 2007; Ricci-Vitiani et al., 2007;
Singh et al., 2004), we have found no evidence that thismarker
is enriched in tumorigenic melanoma cells (Quintana et al.,
2008). Additionally, when we evaluated CD133 expression in
secondary tumors derived from purified CD133 or CD133þ
cells, similarly heterogeneous expression was seen in all tu-
mors irrespective of their cellular origin (Shackleton et al.,2009). This indicates that expression of CD133 is not a heritable
traitofmelanomacells in tumors,but ratherdeterminedasare-
sult of reversible factors. A high priority inmelanoma research
is to understand the functional significance of melanoma cell
interconversion and its relationship to transitory changes in
themalignant behaviour of cells.
For clonal evolution, there is evidence that heterogeneous
genetic changes can evolve within amelanoma tumor. For ex-
ample, sampling of multiple and separate intratumoral re-
gions identified frequent differences in the genomic regions
evaluated (Takata et al., 2000). A critical question that arises
from this observation regards the functional significance of
the development of such genetic heterogeneity; which genetic
changes in cells cause changes in malignant potential? One
example is the amplification in chromosome 13 identified as
a driver of the spontaneous development of metastatic capa-
bility in some melanoma cells through resultant overexpres-
sion of NEDD9 (Kim et al., 2006). Another implication of the
effects of genetic instability in melanoma cells is the possibil-
ity that additional genetic mutations may confer resistance to
therapy, a phenomenon described in other cancers (Edwards
et al., 2008; Sakai et al., 2008; Shah et al., 2007). The clinical im-
portance of this was further highlighted by the identification
of concurrent oncogenic mechanisms that could switch mu-
tant BRAF-driven cells from a state of sensitivity to BRAF-inhi-
bition to a state whose malignant behaviour is enhanced by
BRAF-inhibition (Heidorn et al., 2010). Clonal evolution likely
plays an important role in determining the outcome of mela-
noma in patients. For this reason, determining the degree and
rate of genetic change among melanoma cells is also a high
priority in melanoma research, particularly efforts to identify
those genetic changes that drive the acquisition of enhanced
malignant potential or therapy resistance.6. Conclusion
Significant progress has been made in understanding the
mechanisms throughwhich establishedmelanomas progress.
This has led to the recent development of arguably the most
exciting potential advance in therapy yet seen in this disease,
BRAF-inhibition (Flaherty et al., 2009), for which definitive
clinical trials are currently underway. However the identifica-
tion of resistance mechanisms to BRAF inhibitors (Emery
et al., 2009) and the fact that many melanomas do not carry
suitable mutations (Davies et al., 2002) indicate that much
work remains to be done in understanding the nature of mel-
anoma propagation.
While the CSCmodel offers hope for improved treatment of
some cancers by focusing research and therapies at rare popu-
lations of tumorigenic cells, it is apparent that not all cancers
follow a CSC model. Although evidence from earlier studies
suggested that melanoma might follow a CSC model, recent
studies in more permissive tumorigenesis assays argue
strongly against this possibility. Effective treatments formela-
nomawill thus have to account for the fact that a high propor-
tion of cells must be eliminated. The focus of research efforts
needs tobefirmlyonunraveling themechanisms thatpromote
growth, metastasis and therapy evasion in the cells with tu-
morigenic potential that are so abundant in this disease.
M O L E C U L A R O N C O L O G Y 4 ( 2 0 1 0 ) 4 5 1e4 5 7456Acknowledgements
Thanks to Sean Morrison and Mark Smyth for helpful com-
ments. This work was supported by the Howard Hughes Med-
ical Institute. M.S. was supported by the Peter MacCallum
Cancer Centre, the Australian National Health and Medical
Research Council, the Human Frontiers Science Program,
and Australia Post. E.Q. was supported by the Spanish Minis-
try of Education and the Marie Curie Outgoing International
Fellowship from the European Commission. Apologies to au-
thors whose work was not cited due to space limitations.Note added in proof
As this review was going to press, a publication from Weiss-
man and colleagues appeared in Nature claiming to identify
enriched tumorigenic capacity in the CD271/NGFR/p75þ sub-
fraction of human melanoma cells (Boiko et al., 2010). In the
central experiments of the paper, the authors purified mela-
noma cells from patient tumors (5/6 of the tumors studied
were metastatic lesions – see Supp Tables 2 and 3) before per-
forming intradermal transplants of cells into immunocom-
promised Rag2/gc/ mice. In transplants of
unfractionated cells from three tumors, large numbers
(1000) of cells were generally required to generate tumors.
Using limiting dilution analysis of the data (Hu and Smyth,
2009), themaximum frequency of tumorigenic cells in unfrac-
tionated populations in any tumor was 1/2270 (95% confi-
dence interval 1/550 – 1/9,400, Supp Table 3, tumor 213).
This contrasts starkly with our studies of six melanomas
obtained directly from patients in which the minimum fre-
quency of tumorigenic cells in unfractionated populations
was 1/6 (95% confidence interval 1/2 – 1/15) (Quintana et al.,
2008, Fig 3c, tumors 487, 491 and 498). Furthermore, although
Boiko et al. found that in 5/6 melanomas studied there was
statistically significant (p<0.05) enrichment of tumorigenic
potential in the CD271/NGFR/p75þ fraction, our own studies
of melanoma cells separated according to CD271/NGFR/p75þ
expression and transplanted in more permissive tumorigen-
esis assay conditions have not revealed a similar effect (un-
published). The reasons for these differences are not clear,
but are likely related to differences in the tumorigenesis as-
says used (different tumor digestion protocols, different re-
cipient mice, different injection sites). It will be important
for melanoma biologists to evaluate independently these re-
sults by carefully reproducing the experimental conditions
used in each study. Regardless, studies of the nature and reg-
ulation of tumorigenic melanoma cells hold the best hope of
revealing new therapeutic strategies to combat this disease.R E F E R E N C E S
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